Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11534375rdf:typepubmed:Citationlld:pubmed
pubmed-article:11534375lifeskim:mentionsumls-concept:C0162791lld:lifeskim
pubmed-article:11534375lifeskim:mentionsumls-concept:C1963724lld:lifeskim
pubmed-article:11534375lifeskim:mentionsumls-concept:C0027778lld:lifeskim
pubmed-article:11534375pubmed:issue33lld:pubmed
pubmed-article:11534375pubmed:dateCreated2001-9-5lld:pubmed
pubmed-article:11534375pubmed:abstractTextIn collaboration with the Dutch Institute for Health Care Improvement (CBO) and on the basis of recent developments, new guidelines have been developed for the diagnosis and treatment of HIV-infected patients. The most important recommendations are: Treatment of adult patients is indicated if HIV load > 30,000 RNA copies/ml, or when CD4+ cell count is < 350 x 10(6) cells/l. Treatment of children is indicated if HIV load > 5,000 copies/ml, even when CD4+ cell count is > 500 x 10(6) cells/l. Optimal antiretroviral treatment consists of a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) and one protease inhibitor, or a combination of two NRTIs and one non-nucleoside reverse transcriptase inhibitor. Patients on antiretroviral treatment should be monitored every 3 months. Undetectable HIV load should be the target of first- or second-line antiretroviral treatment. In order to prevent HIV transmission from mother to child, prescription of antiretroviral drugs after the first three months of pregnancy is indicated in pregnant women with a detectable HIV load. Prophylaxis of opportunistic infections can be discontinued if CD4+ cell count recovers above 200 x 10(6)/l. In case of exposure to HIV due to a needle or other occupational accident or unsafe sexual contact, post-exposure prophylaxis should be offered after careful risk evaluation. Preferably, vaccination to prevent pneumococci infections, influenza, hepatitis A or hepatitis B should be given when CD4+ cell count is > 200 x 10(6)/l.lld:pubmed
pubmed-article:11534375pubmed:languagedutlld:pubmed
pubmed-article:11534375pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11534375pubmed:citationSubsetIMlld:pubmed
pubmed-article:11534375pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11534375pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11534375pubmed:statusMEDLINElld:pubmed
pubmed-article:11534375pubmed:monthAuglld:pubmed
pubmed-article:11534375pubmed:issn0028-2162lld:pubmed
pubmed-article:11534375pubmed:authorpubmed-author:DannerS ASAlld:pubmed
pubmed-article:11534375pubmed:authorpubmed-author:LangeJ MJMlld:pubmed
pubmed-article:11534375pubmed:authorpubmed-author:BorleffsJ CJClld:pubmed
pubmed-article:11534375pubmed:authorpubmed-author:van...lld:pubmed
pubmed-article:11534375pubmed:authorpubmed-author:Commissie...lld:pubmed
pubmed-article:11534375pubmed:issnTypePrintlld:pubmed
pubmed-article:11534375pubmed:day18lld:pubmed
pubmed-article:11534375pubmed:volume145lld:pubmed
pubmed-article:11534375pubmed:ownerNLMlld:pubmed
pubmed-article:11534375pubmed:authorsCompleteYlld:pubmed
pubmed-article:11534375pubmed:pagination1585-9lld:pubmed
pubmed-article:11534375pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:meshHeadingpubmed-meshheading:11534375...lld:pubmed
pubmed-article:11534375pubmed:year2001lld:pubmed
pubmed-article:11534375pubmed:articleTitle[CBO guidelines 'Antiretroviral therapy in the Netherlands'].lld:pubmed
pubmed-article:11534375pubmed:affiliationUniversitair Medisch Centrum, afd. Interne Geneeskunde, onderafd. Infectieziekten en Aids, Postbus 85.500, 3508 GA Utrecht. j.c.c.borleffs@azu.nllld:pubmed
pubmed-article:11534375pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11534375pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:11534375pubmed:publicationTypeReviewlld:pubmed